ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses11.05 M9.87 M10.06 M9.08 M7.99 M36.99 MResearch & development27.73 M23.68 M26.01 M27.08 M28.14 M104.91 MOperating income10.63 M4.73 M29.63 M17.86 M35.55 M87.76 MNon-Operating Income, Total——2.36 M4.89 M207 K—Interest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses——1.2 M2.4 M100 K—Unusual income/expense——1.16 M2.49 M107 K—Pretax income10.76 M2.3 M30.48 M19.96 M35.09 M87.83 MEquity in earnings——————Taxes88 K-93 K119 K27 K161 K214 KNon-controlling/minority interest——————After tax other income/expense-99 K326 K10 K25 K0361 KNet income before discontinued operations10.67 M2.05 M30.6 M19.99 M34.93 M87.56 MDiscontinued operations——————Net income10.67 M2.05 M30.6 M19.99 M34.93 M87.56 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders9.38 M2.05 M30.6 M19.99 M34.93 M87.56 MBasic earnings per share (Basic EPS)0.05-0.09-0.14-0.08-0.11-0.42Diluted earnings per share (Diluted EPS)0.04-0.08-0.14-0.08-0.11-0.41Average basic shares outstanding208.34 M201.7 M220.3 M257 M304.3 M983.3 MDiluted shares outstanding214.32 M201.7 M220.3 M257 M304.3 M983.3 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)1.22 M1.23 M1.02 M993 K989 K4.24 M
Sangamo Therapeutics Inc
Sangamo Therapeutics, Inc. is an American biotechnology company based in Brisbane, California, that develops cell and gene therapies for severe genetic diseases.